These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
468 related articles for article (PubMed ID: 28786691)
1. Current and developing therapies for the treatment of multi drug resistant tuberculosis (MDR-TB) in India. Muniyandi M; Ramachandran R Expert Opin Pharmacother; 2017 Sep; 18(13):1301-1309. PubMed ID: 28786691 [TBL] [Abstract][Full Text] [Related]
2. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis. Centers for Disease Control and Prevention MMWR Recomm Rep; 2013 Oct; 62(RR-09):1-12. PubMed ID: 24157696 [TBL] [Abstract][Full Text] [Related]
3. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial. Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149 [TBL] [Abstract][Full Text] [Related]
4. Recent controversies about MDR and XDR-TB: Global implementation of the WHO shorter MDR-TB regimen and bedaquiline for all with MDR-TB? Dheda K; Cox H; Esmail A; Wasserman S; Chang KC; Lange C Respirology; 2018 Jan; 23(1):36-45. PubMed ID: 28850767 [TBL] [Abstract][Full Text] [Related]
5. Current therapies for the treatment of multidrug-resistant tuberculosis in children in India. Mukherjee A; Lodha R; Kabra SK Expert Opin Pharmacother; 2017 Oct; 18(15):1595-1606. PubMed ID: 28847228 [TBL] [Abstract][Full Text] [Related]
6. The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens. Khan U; Huerga H; Khan AJ; Mitnick CD; Hewison C; Varaine F; Bastard M; Rich M; Franke MF; Atwood S; Khan PY; Seung KJ BMC Infect Dis; 2019 Aug; 19(1):733. PubMed ID: 31429722 [TBL] [Abstract][Full Text] [Related]
7. Multi and extensively drug-resistant pulmonary tuberculosis: advances in diagnosis and management. Pontali E; Visca D; Centis R; D'Ambrosio L; Spanevello A; Migliori GB Curr Opin Pulm Med; 2018 May; 24(3):244-252. PubMed ID: 29470252 [TBL] [Abstract][Full Text] [Related]
8. Unacceptable treatment outcomes and associated factors among India's initial cohorts of multidrug-resistant tuberculosis (MDR-TB) patients under the revised national TB control programme (2007-2011): Evidence leading to policy enhancement. Parmar MM; Sachdeva KS; Dewan PK; Rade K; Nair SA; Pant R; Khaparde SD PLoS One; 2018; 13(4):e0193903. PubMed ID: 29641576 [TBL] [Abstract][Full Text] [Related]
9. Applicability of the shorter 'Bangladesh regimen' in high multidrug-resistant tuberculosis settings. Sotgiu G; Tiberi S; Centis R; D'Ambrosio L; Fuentes Z; Zumla A; Migliori GB Int J Infect Dis; 2017 Mar; 56():190-193. PubMed ID: 27816662 [TBL] [Abstract][Full Text] [Related]
10. ▼Bedaquiline for multidrug-resistant tuberculosis. Drug Ther Bull; 2014 Nov; 52(11):129-32. PubMed ID: 25395481 [TBL] [Abstract][Full Text] [Related]
11. Cost comparison of nine-month treatment regimens with 20-month standardized care for the treatment of rifampicin-resistant/multi-drug resistant tuberculosis in Nigeria. Bada FO; Blok N; Okpokoro E; Dutt S; Akolo C; Dakum P; Abimiku A PLoS One; 2020; 15(12):e0241065. PubMed ID: 33259492 [TBL] [Abstract][Full Text] [Related]
12. Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis. Schnippel K; Firnhaber C; Conradie F; Ndjeka N; Sinanovic E Appl Health Econ Health Policy; 2018 Feb; 16(1):43-54. PubMed ID: 28980217 [TBL] [Abstract][Full Text] [Related]
13. Identification of patients who could benefit from bedaquiline or delamanid: a multisite MDR-TB cohort study. Bonnet M; Bastard M; du Cros P; Khamraev A; Kimenye K; Khurkhumal S; Hayrapetyan A; Themba D; Telnov A; Sanchez-Padilla E; Hewison C; Varaine F Int J Tuberc Lung Dis; 2016 Feb; 20(2):177-86. PubMed ID: 26792469 [TBL] [Abstract][Full Text] [Related]
14. Management of drug resistantTB in patients with HIV co-infection. Pontali E; Sotgiu G; Centis R; D'Ambrosio L; Spanevello A; Migliori GB Expert Opin Pharmacother; 2015; 16(18):2737-50. PubMed ID: 26478945 [TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany. Wirth D; Dass R; Hettle R BMC Health Serv Res; 2017 Mar; 17(1):182. PubMed ID: 28270207 [TBL] [Abstract][Full Text] [Related]
16. Early outcome and safety of bedaquiline-containing regimens for treatment of MDR- and XDR-TB in China: a multicentre study. Gao M; Gao J; Xie L; Wu G; Chen W; Chen Y; Pei Y; Li G; Liu Y; Shu W; Fan L; Wu Q; Du J; Chen X; Tang P; Xiong Y; Li M; Cai Q; Jin L; Mei Z; Pang Y; Li L Clin Microbiol Infect; 2021 Apr; 27(4):597-602. PubMed ID: 32553880 [TBL] [Abstract][Full Text] [Related]
17. Treatment outcomes of multidrug resistant tuberculosis (MDR TB) treated with bedaquiline under programmatic management of drug resistant tuberculosis at a tertiary care hospital in Punjab, India. Kumari DS; Gupta DA; Chopra DV; Kaur DS Indian J Tuberc; 2024; 71 Suppl 1():S67-S71. PubMed ID: 39067958 [TBL] [Abstract][Full Text] [Related]
18. Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis. Pym AS; Diacon AH; Tang SJ; Conradie F; Danilovits M; Chuchottaworn C; Vasilyeva I; Andries K; Bakare N; De Marez T; Haxaire-Theeuwes M; Lounis N; Meyvisch P; Van Baelen B; van Heeswijk RP; Dannemann B; Eur Respir J; 2016 Feb; 47(2):564-74. PubMed ID: 26647431 [TBL] [Abstract][Full Text] [Related]
19. Modeling the impact of bedaquiline treatment strategies on the multidrug-resistant tuberculosis burden in India. Mehra M; Kambili C; Potluri R; Rhines A; Singh V; Thomas A Int J Tuberc Lung Dis; 2017 Aug; 21(8):902-909. PubMed ID: 28786799 [TBL] [Abstract][Full Text] [Related]
20. A pragmatic randomized controlled trial to evaluate the efficacy and safety of an oral short-course regimen including bedaquiline for the treatment of patients with multidrug-resistant tuberculosis in China: study protocol for PROSPECT. Gao J; Gao M; Du J; Pang Y; Mao G; Lounis N; Bakare N; Jiang Y; Zhan Y; Liu Y; Li L; Trials; 2024 Apr; 25(1):227. PubMed ID: 38561815 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]